Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (41-50 of 181) with videos related to

Pageof 19
Sort By:
Leukemia & Lymphoma|February 28, 2007
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phaseAlfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|February 22, 2003
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndromeJorge Cortes, Patricia Ault, Charles Koller, et al.
Clinical Pharmacology and Therapeutics|August 5, 2020
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic LeukemiaSathej Gopalakrishnan, William Wierda, Brenda Chyla, et al.
Journal of Clinical Pathology|November 24, 2018
Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluationPrajwal Boddu, Beenu Thakral, Ahmed Alhuraiji, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2014
Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplantRohtesh S Mehta, Antonio Di Stasi, Chitra Hosing, et al.
Cancer|July 22, 2014
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemiaPreetesh Jain, Hun Ju Lee, Wei Qiao, et al.
British Journal of Haematology|June 18, 2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaFabio P S Santos, Hagop Kantarjian, Carmen Fava, et al.
Cancer|September 19, 2008
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 yearsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Cancer|January 26, 2006
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcomeHagop Kantarjian, Susan O'brien, Jorge Cortes, et al.
Biomed Research International|February 6, 2015
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabineTalha Badar, Jorge Cortes, Gautam Borthakur, et al.
Pageof 19

Showing results (41-50 of 181) with videos related to

Sort By:
Pageof 19
Leukemia & Lymphoma|February 28, 2007
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phaseAlfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|February 22, 2003
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndromeJorge Cortes, Patricia Ault, Charles Koller, et al.
Clinical Pharmacology and Therapeutics|August 5, 2020
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic LeukemiaSathej Gopalakrishnan, William Wierda, Brenda Chyla, et al.
Journal of Clinical Pathology|November 24, 2018
Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluationPrajwal Boddu, Beenu Thakral, Ahmed Alhuraiji, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2014
Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplantRohtesh S Mehta, Antonio Di Stasi, Chitra Hosing, et al.
Cancer|July 22, 2014
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemiaPreetesh Jain, Hun Ju Lee, Wei Qiao, et al.
British Journal of Haematology|June 18, 2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaFabio P S Santos, Hagop Kantarjian, Carmen Fava, et al.
Cancer|September 19, 2008
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 yearsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Cancer|January 26, 2006
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcomeHagop Kantarjian, Susan O'brien, Jorge Cortes, et al.
Biomed Research International|February 6, 2015
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabineTalha Badar, Jorge Cortes, Gautam Borthakur, et al.
Pageof 19